Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group.
OBJECTIVE
This prospective randomized trial was used to compare predictive factors for organ confined margin negative status after radical prostatectomy with and without a 3-month course of neoadjuvant androgen withdrawal therapy.


METHODS
A total of 213 patients with localized adenocarcinoma of the prostate were randomized to radical prostatectomy with or without a 3-month course of 300 mg. neoadjuvant cyproterone acetate daily. Multivariate logistic regression analysis was used to determine significant predictors of organ confined margin negative status after radical prostatectomy in both groups. Parameters evaluated included baseline prostate specific antigen (PSA 4 or less, 4.1 to 10, greater than 10 ng./ml.), clinical stage (T2c versus T2b or less), biopsy Gleason score and percentage of surface area of biopsies involved with cancer. The multivariate analysis was repeated with PSA density and the natural logarithm of PSA to optimize the model.


RESULTS
In the radical prostatectomy alone arm a model incorporating only PSA density was the best predictor of organ confined margin negative status. In the neoadjuvant androgen withdrawal therapy arm a model incorporating biopsy Gleason score, PSA density and clinical stage was the best predictor.


CONCLUSIONS
The conventional predictors of pathology at radical prostatectomy, biopsy Gleason score, PSA density and clinical stage retain significance as predictors in patients treated with a 3-month course of neoadjuvant androgen withdrawal therapy before radical prostatectomy.
Rabbani
F
F
Urology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Goldenberg
S L
SL
Klotz
L H
LH
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D016009:Chi-Square Distribution; D017373:Cyproterone Acetate / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017373:Cyproterone Acetate; D017430:Prostate-Specific Antigen